Search over 3,000 reports

    Diabetic Retinopathy - Competitive Landscape, Pipeline and Market Analysis, 2017

    Diabetic Retinopathy - Competitive Landscape, Pipeline and Market Analysis, 2017
    Date: Dec, 2017
    Type: Pharmaceutical
    Pages: 100
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DISR0013
    DelveInsight's Diabetic Retinopathy - Competitive Landscape, Pipeline and Market Analysis, 2017 report provides an overview of the epidemiology trends of Diabetic Retinopathy in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes the historical and forecasted epidemiology data for Diabetic Retinopathy prevalent or incident cases segmented by age, sex and subpopulations. The report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Diabetic Retinopathy. Further, therapeutic assessment of pipeline products by mechanism of action (MoA), route of administration (RoA), molecule type, along with latest updates are covered in this report. A comprehensive review of the market trends, drivers, barriers, key company profiles including its business and product developments are also detailed here. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by DelveInsight's team of industry experts.

    Key Coverage and Benefits

    • The report will help in developing business strategies by understanding the trends shaping and driving the global Diabetic Retinopathy market
    • Identifying prevalent patient populations as well as risk factors in the global Diabetic retinopathy market will help to improve product design, pricing, and launch plans
    • To understand the current pipeline scenario of different companies so as to make the research activity more robust and competitive
    • To understand the future market competition in the global Diabetic Retinopathy market and Insightful review of the key market drivers and barriers
    • The report also covers the detailed global historical and forecasted Diabetic Retinopathy market covering United States, European Union 5 (EU5 - Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023
    Report Introduction
    Diabetic Retinopathy (DR) Market Overview at a Glance
    • Global Market Size of DR in 2016
    • Global Market Size of DR in 2023
    Diabetic Retinopathy: Overview
    • Stages
    • Symptoms
    • Types
    • Pathophysiology
    • Etiology
    • Risk Factors
    • Disease Burden
    Unmet Needs
    Epidemiology of Diabetic Retinopathy in 7MM (2013-2023)
    United States
    • Sex Specific Prevalence of Diabetes Retinopathy in US
    • Age-Specific Prevalence of Diabetes Retinopathy in US
    • Sub-type Prevalence of Diabetes Retinopathy in US
    EU5
    United Kingdom
    • Sex Specific Prevalence of Diabetes Retinopathy in UK
    • Age-Specific Prevalence of Diabetes Retinopathy in UK
    • Sub-type Prevalence of Diabetes Retinopathy in UK
    France
    • Sex Specific Prevalence of Diabetes Retinopathy in France
    • Age-Specific Prevalence of Diabetes Retinopathy in France
    • Sub-type Prevalence of Diabetes Retinopathy in France
    Italy
    • Sex Specific Prevalence of Diabetes Retinopathy in Italy
    • Age-Specific Prevalence of Diabetes Retinopathy in Italy
    • Sub-type Prevalence of Diabetes Retinopathy in Italy
    Germany
    • Sex Specific Prevalence of Diabetes Retinopathy in Germany
    • Age-Specific Prevalence of Diabetes Retinopathy in Germany
    • Sub-type Prevalence of Diabetes Retinopathy in Germany
    Spain
    • Sex Specific Prevalence of Diabetes Retinopathy in Spain
    • Age-Specific Prevalence of Diabetes Retinopathy in Spain
    • Sub-type Prevalence of Diabetes Retinopathy in Spain
    Japan
    • Sex Specific Prevalence of Diabetes Retinopathy in Japan
    • Age-Specific Prevalence of Diabetes Retinopathy in Japan
    • Sub-type Prevalence of Diabetes Retinopathy in Japan
    Treatment Algorithm
    Global Diabetic Retinopathy: Country-Wise Market Analysis
    Total Market Size of Diabetic Retinopathy (2013-2023)
    • United States
    • EU5
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Japan
    Competitive Landscape
    Marketed Drugs
    EYLEA
    Description
    Regulatory Milestones
    Advantages and Disadvantages
    Product Profile
    Safety & Efficacy
    Side effects of EYLEA
    Other Marketed Drug profiles in detailed report
    Pipeline Therapeutics
    An Overview of Pipeline Products for Diabetic Retinopathy and Diabetic Macular Edema
    Comparative Analysis
    Pipeline Therapeutics
    Pipeline Therapeutics Overview
    Late Stage Products (Filed and Phase III)
    Comparative Analysis
    Mid Stage Products (Phase II)
    Comparative Analysis
    Early Stage Products (Phase I and IND)
    Comparative Analysis
    Pre-Clinical and Discovery Products
    Comparative Analysis
    Drug Candidate Profile
    Emixustat HCl: Acucela Inc.
    Product Description
    Research and Development
    Other Development Activities (Deals and Partnership )
    Other Pipeline Drug profiles in detailed report
    Therapeutic Assessment
    Assessment by Product Type
    Assessment by Phase for Monotherapy
    Assessment by Phase for Combination therapy
    Assessment by Molecule Type
    Assessment by Stage and Molecule Type
    Assessment by Route of AdministrationAssessment by Stage and Route of Administration
    Dormant Products
    Discontinued Products
    Analyst's Insights
    Market Drivers
    Market Barriers
    Appendix
    Report Methodology
    Consulting Services
    Disclaimer
    About DelveInsight
    Table 1: Prevalent Population of Diabetic Retinopathy in United States (2013-2023)
    Table 2: Sex Specific Prevalence of Diabetes Retinopathy in United States (2013-2023)
    Table 3: Age-Specific Prevalence of Diabetes Retinopathy in United States (2013-2023)
    Table 4: Sub-type Specific Prevalence of Diabetes Retinopathy in United States (2013-2023)
    Table 5: Prevalent Population of Diabetic Retinopathy in United Kingdom (2013-2023)
    Table 6: Sex Specific Prevalence of Diabetes Retinopathy in United Kingdom (2013-2023)
    Table 7: Age-Specific Prevalence of Diabetes Retinopathy in United Kingdom (2013-2023)
    Table 8: Sub-type Specific Prevalence of Diabetes Retinopathy in United Kingdom (2013-2023)
    Table 9: Prevalent Population of Diabetic Retinopathy in France (2013-2023)
    Table 10: Sex Specific Prevalence of Diabetes Retinopathy in France (2013-2023)
    Table 11: Age-Specific Prevalence of Diabetes Retinopathy in France (2013-2023)
    Table 12: Sub-type Specific Prevalence of Diabetes Retinopathy in France (2013-2023)
    Table 13: Prevalent Population of Diabetic Retinopathy in Italy (2013-2023)
    Table 14: Sex Specific Prevalence of Diabetes Retinopathy in Italy (2013-2023)
    Table 15: Age-Specific Prevalence of Diabetes Retinopathy in Italy (2013-2023)
    Table 16: Sub-type Specific Prevalence of Diabetes Retinopathy in Italy (2013-2023)
    Table 17: Prevalent Population of Diabetic Retinopathy in Germany (2013-2023)
    Table 18: Sex Specific Prevalence of Diabetes Retinopathy in Germany (2013-2023)
    Table 19: Age-Specific Prevalence of Diabetes Retinopathy in Germany (2013-2023)
    Table 20: Sub-type Specific Prevalence of Diabetes Retinopathy in Germany (2013-2023)
    Table 21: Prevalent Population of Diabetic Retinopathy in Spain (2013-2023)
    Table 22: Sex Specific Prevalence of Diabetes Retinopathy in Spain (2013-2023)
    Table 23: Age-Specific Prevalence of Diabetes Retinopathy in Spain (2013-2023)
    Table 24: Sub-type Specific Prevalence of Diabetes Retinopathy in Spain (2013-2023)
    Table 25: Prevalent Population of Diabetic Retinopathy in Japan (2013-2023)
    Table 26: Sex Specific Prevalence of Diabetes Retinopathy in Japan (2013-2023)
    Table 27: Age-Specific Prevalence of Diabetes Retinopathy in Japan (2013-2023)
    Table 28: Sub-type Specific Prevalence of Diabetes Retinopathy in Japan (2013-2023)
    Table 29: Total Market size of Diabetic Retinopathy in USD Billion (2013-2023)
    Table 30: United States Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
    Table 31: United Kingdom Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
    Table 32: Germany Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
    Table 33: France Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
    Table 34: Italy Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
    Table 35: Spain Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
    Table 36: Japan Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
    Table 37: Pipeline Therapeutics for Diabetic Retinopathy Drugs, 2017
    Table 38: Comparative Table for Diabetic Retinopathy Drugs, 2017
    Table 39: Late Stage Products (Filed and Phase III), 2017
    Table 40: Mid Stage Products (Phase II), 2017
    Table 41: Early Stage Products (Phase I), 2017
    Table 42: Pre-Clinical and Discovery Products, 2017
    Table 49: Therapeutic Assessment, 2017
    Table 50: Dormant Products, 2017
    Table 51: Discontinued Products, 2017
    Figure 1: Risk Factors of Diabetic Retinopathy
    Figure 2: Prevalent Population of Diabetic Retinopathy in United States (2013-2023)
    Figure 3: Sex Specific Prevalence of Diabetes Retinopathy in United States (2013-2023)
    Figure 4: Age-Specific Prevalence of Diabetes Retinopathy in United States (2013-2023)
    Figure 5: Sub-type Specific Prevalence of Diabetes Retinopathy in United States (2013-2023)
    Figure 6: Prevalent Population of Diabetes Retinopathy in United Kingdom (2013-2023)
    Figure 7: Sex Specific Prevalence of Diabetes Retinopathy in United Kingdom (2013-2023)
    Figure 8: Age-Specific Prevalence of Diabetes Retinopathy in United Kingdom (2013-2023)
    Figure 9: Sub-type Specific Prevalence of Diabetes Retinopathy in United Kingdom (2013-2023)
    Figure 10: Prevalent Population of Diabetic Retinopathy in France (2013-2023)
    Figure 11: Sex Specific Prevalence of Diabetes Retinopathy in France (2013-2023)
    Figure 12: Age-Specific Prevalence of Diabetes Retinopathy in France (2013-2023)
    Figure 13: Sub-type Specific Prevalence of Diabetes Retinopathy in France (2013-2023)
    Figure 14: Prevalent Population of Diabetic Retinopathy in Italy (2013-2023)
    Figure 15: Sex Specific Prevalence of Diabetes Retinopathy in Italy (2013-2023)
    Figure 16: Age-Specific Prevalence of Diabetes Retinopathy in Italy (2013-2023)
    Figure 17: Sub-type Specific Prevalence of Diabetes Retinopathy in Italy (2013-2023)
    Figure 18: Prevalent Population of Diabetic Retinopathy in Germany (2013-2023)
    Figure 19: Sex Specific Prevalence of Diabetes Retinopathy in Germany (2013-2023)
    Figure 20: Age-Specific Prevalence of Diabetes Retinopathy in Germany (2013-2023)
    Figure 21: Sub-type Specific Prevalence of Diabetes Retinopathy in Germany (2013-2023)
    Figure 22: Prevalent Population of Diabetic Retinopathy Spain (2013-2023)
    Figure 23: Sex Specific Prevalence of Diabetes Retinopathy in Spain (2013-2023)
    Figure 24: Age-Specific Prevalence of Diabetes Retinopathy in Spain (2013-2023)
    Figure 25: Sub-type Specific Prevalence of Diabetes Retinopathy in Spain (2013-2023)
    Figure 26: Prevalent Population of Diabetic Retinopathy in Japan (2013-2023)
    Figure 27: Sex Specific Prevalence of Diabetes Retinopathy in Japan (2013-2023)
    Figure 28: Age-Specific Prevalence of Diabetes Retinopathy in Japan (2013-2023)
    Figure 29: Sub-type Specific Prevalence of Diabetes Retinopathy in Japan (2013-2023)
    Figure 30: Total Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
    Figure 31: United States Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
    Figure 32: United Kingdom Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
    Figure 33: Germany Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
    Figure 34: France Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
    Figure 35: Italy Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
    Figure 36: Spain Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
    Figure 37: Japan Market Size of Diabetic Retinopathy in USD, Billion (2013-2023)
    Figure 38: Marketed and Pipeline drugs for Diabetic Retinopathy, 2017
    Figure 39: Vyndaqel Historical and forecasted Global Market Size in USD, Million (2016-2022)
    Figure 40: Total Products for Diabetic Retinopathy, 2017
    Figure 41: Late Stage Products (Filed and Phase III), 2017
    Figure 42: Mid Stage Products (Phase II), 2017
    Figure 43: Early Stage Products (Phase I), 2017
    Figure 44: Pre-Clinical and Discovery Products, 2017
    Figure 45: Patisiran Forecasted Sales in USD, Million (2018-2022)
    Figure 46: Number of Monotherapy Products for Diabetic Retinopathy, 2017
    Figure 47: Number of Combination Therapy Products for Diabetic Retinopathy, 2017
    Figure 48: Percentage of pipeline drugs by Molecule Type (%), 2017
    Figure 49: Assessment by Stage and Molecule Type, 2017
    Figure 50: Pipeline Drugs by Route of Administration, 2017
    Figure 51: Assessment by Stage and Route of Administration, 2017
    Figure 52: Dormant Products, 2017
    Diabetic Retinopathy (7MM)

    Diabetic Retinopathy Forecasting

    Diabetic Retinopathy Sales forecasting

    Diabetic Retinopathy Segments

    Diabetic Retinopathy Epidemiology

    Diabetic Retinopathy Pipeline products and technologies

    Diabetic Retinopathy Competitive landscape

    Diabetic Retinopathy SWOT analysis

    • Single User License
      (20% Off)
      $6,950.00
    • Site License
      (30% Off)
      $13,900.00
    • Global License
      (40% Off)
      $20,850.00

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap